Olanzapine counteracts stress-induced anxiety-like behavior in rats

Neuroscience Letters

Volumn 438, Issue 2, 2008, Pages 146-149

  Locchi, Federica ^a   Dall'Olio, Rossella ^a   Gandolfi, Ottavio ^a   Rimondini, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Allopregnanolone; Anxiety; EPM; GABA; Olanzapine; Rat

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR; FINASTERIDE; OLANZAPINE; STEROID 5ALPHA REDUCTASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GABAERGIC SYSTEM; IMMOBILIZATION STRESS; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; BRAIN; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; FINASTERIDE; GAMMA-AMINOBUTYRIC ACID; MALE; MAZE LEARNING; PREGNANOLONE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; RESTRAINT, PHYSICAL; STRESS, PSYCHOLOGICAL; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 43849098918     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.04.017     Document Type: Article

References (39)

1. Amat J., Baratta M.V., Paul E., Bland S.T., Watkins L.R., and Maier S.F. Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat. Neurosci. 8 (2005) 365-371
2. Arnt J., and Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
3. Bakshi V.P., Swerdlow N.R., Braff D.L., and Geyer M.A. Reversal of isolation rearing-induced deficits in prepulse inhibition by Seroquel and olanzapine. Biol. Psychiatry 43 (1998) 436-445
4. Conley R.R., and Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 158 (2001) 765-774
5. Dall'olio R., Rimondini R., Locchi F., Voltattorni M., and Gandolfi O. An ionotropic but not a metabotropic glutamate agonist potentiates the pharmacological effects of olanzapine in the rat. Behav. Pharmacol. 16 (2005) 635-642
6. Diorio D., Viau V., and Meaney M.J. The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress. J. Neurosci. 13 (1993) 3839-3847
7. Farnbach-Pralong D., Bradbury R., Copolov D., and Dean B. Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors. Eur. J. Pharmacol. 349 (1998) R7-R8
8. Finn D.A., Beadles-Bohling A.S., Beckley E.H., Ford M.M., Gililland K.R., Gorin-Meyer R.E., and Wiren K.M. A new look at the 5-alpha-reductase inhibitor finasteride. CNS Drug Rev. 12 (2006) 53-76
9. Frye C.A., and Seliga A.M. Olanzapine's effects to reduce fear and anxiety and enhance social interactions coincide with increased progestin concentrations of ovariectomized rats. Psychoneuroendocrinology 28 (2003) 657-673
10. Fu Y., Zhu Z.T., Chen L.J., Yu L.P., and Jin G.Z. Behavioral characteristics of olanzapine: an atypical neuroleptic. Acta Pharmacol. Sin. 21 (2000) 329-334
11. Inoue T., Tsuchiya K., and Koyama T. Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear. Pharmacol. Biochem. Behav. 55 (1996) 195-201
12. Korte S.M. Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci. Biobehav. Rev. 25 (2001) 117-142
13. Marx C.E., Duncan G.E., Gilmore J.H., Lieberman J.A., and Morrow A.L. Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol. Psychiatry 47 (2000) 1000-1004
14. Marx C.E., VanDoren M.J., Duncan G.E., Lieberman J.A., and Morrow A.L. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 28 (2003) 1-13
15. McBlane J.W., and Handley S.L. Effects of two stressors on behaviour in the elevated X-maze: preliminary investigation of their interaction with 8-OH-DPAT. Psychopharmacology 116 (1994) 173-182
16. Mechiel K.S., and De Boer S.F. A robust animal model of state anxiety: fear-potentiated behaviour in the elevated plus-maze. Eur. J. Pharmacol. 463 (2003) 163-175
17. Meehan K., Zhang F., David S., Tohen M., Janicak P., Small J., Koch M., Rizk R., Walker D., Tran P., and Breier A. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J. Clin. Psychopharmacol. 21 (2001) 389-397
18. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 70 (2003) 83-244
19. Möller C., Wiklund L., Thorsell A., Hyytia P., and Heilig M. Decreased measures of experimental anxiety in rats bred for high alcohol preference. Alcohol. Clin. Exp. Res. 21 (1997) 656-660
20. Moore N.A. Behavioural pharmacology of the new generation of antipsychotic agents. Br. J. Psychiatry Suppl. (1999) 5-11
21. Moore N.A., Tye N.C., Axton M.S., and Risius F.C. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J. Pharmacol. Exp. Ther. 262 (1992) 545-551
22. Nemeroff C.B. Use of atypical antipsychotics in refractory depression and anxiety. J. Clin. Psychiatry 66 Suppl. 8 (2005) 13-21
23. Overstreet D.H., Knapp D.J., and Breese G.R. Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol. Clin. Exp. Res. 31 (2007) 1473-1481
24. Paul S.M., and Purdy R.H. Neuroactive steroids. FASEB J. 6 (1992) 2311-2322
25. Pellow S., Chopin P., File S.E., and Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14 (1985) 149-167
26. Petty F., Brannan S., Casada J., Davis L.L., Gajewski V., Kramer G.L., Stone R.C., Teten A.L., Worchel J., and Young K.A. Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int. Clin. Psychopharmacol. 16 (2001) 331-337
27. Quirk G.J., and Gehlert D.R. Inhibition of the amygdala: key to pathological states?. Ann. N. Y. Acad. Sci. 985 (2003) 263-272
28. Ragozzino M.E. The contribution of the medial prefrontal cortex, orbitofrontal cortex, and dorsomedial striatum to behavioral flexibility. Ann. N. Y. Acad. Sci. 1121 (2007) 355-375
29. Ridderinkhof K.R., Ullsperger M., Crone E.A., and Nieuwenhuis S. The role of the medial frontal cortex in cognitive control. Science 306 (2004) 443-447
30. Sepede G., De Berardis D., Gambi F., Campanella D., La Rovere R., D'Amico M., Cicconetti A., Penna L., Peca S., Carano A., Mancini E., Salerno R.M., and Ferro F.M. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J. Clin. Psychopharmacol. 26 (2006) 45-49
31. Skilbeck K.J., O'Reilly J.N., Johnston G.A., and Hinton T. The effects of antipsychotic drugs on GABA(A) receptor binding depend on period of drug treatment and binding site examined. Schizophr. Res. 90 (2007) 76-80
32. Skilbeck K.J., O'Reilly J.N., Johnston G.A., and Hinton T. Antipsychotic drug administration differentially affects [(3)H]muscimol and [(3)H]flunitrazepam GABA(A) receptor binding sites. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 492-498
33. Skilbeck K.J., Hinton T., and Johnston G.A. Sex-differences and stress: effects on regional high and low affinity [(3)H]GABA binding. Neurochem. Int. 52 (2008) 1212-1219
34. Spencer S.J., Buller K.M., and Day T.A. Medial prefrontal cortex control of the paraventricular hypothalamic nucleus response to psychological stress: possible role of the bed nucleus of the stria terminalis. J. Comp Neurol. 481 (2005) 363-376
35. Sullivan R.M., and Gratton A. Prefrontal cortical regulation of hypothalamic-pituitary-adrenal function in the rat and implications for psychopathology: side matters. Psychoneuroendocrinology 27 (2002) 99-114
36. Thorsell A., Michalkiewicz M., Dumont Y., Quirion R., Caberlotto L., Rimondini R., Mathe A.A., and Heilig M. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 12852-12857
37. Twyman R.E., and Macdonald R.L. Neurosteroid regulation of GABAA receptor single-channel kinetic properties of mouse spinal cord neurons in culture. J. Physiol. 456 (1992) 215-245
38. Van Reenen C.G., O'Connell N.E., Van der Werf J.T., Korte S.M., Hopster H., Jones R.B., and Blokhuis H.J. Responses of calves to acute stress: individual consistency and relations between behavioral and physiological measures. Physiol. Behav. 85 (2005) 557-570
39. Verma V., Rasmussen K., and Dawe G.S. Effects of short-term and chronic olanzapine treatment on immediate early gene protein and tyrosine hydroxylase immunoreactivity in the rat locus coeruleus and medial prefrontal cortex. Neuroscience 143 (2006) 573-585